162 related articles for article (PubMed ID: 16456500)
1. Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth.
Desrosiers P; O'Brien F; Blethen S
Pediatr Endocrinol Rev; 2005 Feb; 2 Suppl 3():327-31. PubMed ID: 16456500
[TBL] [Abstract][Full Text] [Related]
2. The GHMonitorSM Registry: an update of the last three years.
Steelman J
Pediatr Endocrinol Rev; 2006 Dec; 4 Suppl 1():91-4. PubMed ID: 17261976
[TBL] [Abstract][Full Text] [Related]
3. An overview of the GHMonitor, a registry of children treated with Saizen somatropin [recombinant hGH for injection].
Blethen SL; O'Brien F; Reinhart R
Pediatr Endocrinol Rev; 2005 Feb; 2 Suppl 3():324-6. PubMed ID: 16456499
[TBL] [Abstract][Full Text] [Related]
4. Update from the GHMonitorSM observational registry in children treated with recombinant human growth hormone (Saizen).
Plotnick L; Rapaport R; Desrosiers P; Fuqua JS
Pediatr Endocrinol Rev; 2009 Jan; 6 Suppl 2():278-82. PubMed ID: 19337182
[TBL] [Abstract][Full Text] [Related]
5. Issues and trends in pediatric growth hormone therapy--an update from the GHMonitor observational registry.
Pitukcheewanont P; Desrosiers P; Steelman J; Rapaport R; Fuqua JS; Kreher NC; Hamlett A
Pediatr Endocrinol Rev; 2008 Feb; 5 Suppl 2():702-7. PubMed ID: 18317441
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of concordance in growth hormone therapy.
Kapoor RR; Burke SA; Sparrow SE; Hughes IA; Dunger DB; Ong KK; Acerini CL
Arch Dis Child; 2008 Feb; 93(2):147-8. PubMed ID: 17768149
[TBL] [Abstract][Full Text] [Related]
7. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
9. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature.
Ranke MB; Lindberg A; Price DA; Darendeliler F; Albertsson-Wikland K; Wilton P; Reiter EO;
Horm Res; 2007; 68(2):53-62. PubMed ID: 17228181
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle.
Brearley C; Priestley A; Leighton-Scott J; Christen M
BMC Clin Pharmacol; 2007 Oct; 7():10. PubMed ID: 17922895
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of final height in patients with pituitary growth hormone deficiency who were treated with growth hormone replacement].
Korpal-Szczyrska M; Dorant B; Kamińska H; Birkholz D; Niedźwiecki M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(1):31-4. PubMed ID: 16704859
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age.
Cutfield WS; Lundgren F
Horm Res; 2009 Jan; 71 Suppl 1():39-45. PubMed ID: 19153504
[TBL] [Abstract][Full Text] [Related]
13. Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients.
Pfützner A; Hartmann K; Winter F; Fuchs GS; Kappelgaard AM; Rohrer TR
Clin Ther; 2010 Oct; 32(11):1918-34. PubMed ID: 21095487
[TBL] [Abstract][Full Text] [Related]
14. The impact of fasting and treatment omission on susceptibility to hypoglycaemia in children and adolescents with GH and cortisol insufficiency.
Johnstone HC; McNally RJ; Cheetham TD
Clin Endocrinol (Oxf); 2008 Sep; 69(3):436-42. PubMed ID: 18248651
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone treatment in prepubertal children with celiac disease and growth hormone deficiency.
Giovenale D; Meazza C; Cardinale GM; Farinelli E; Mastrangelo C; Messini B; Citro G; Del Vecchio M; Di Maio S; Possenti I; Bozzola M
J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):433-7. PubMed ID: 18030209
[TBL] [Abstract][Full Text] [Related]
16. Factors determining patient choice of device for GH therapy.
Wickramasuriya BP; Casey A; Akhtar S; Zia R; Ehtisham S; Barrett TG; Shaw NJ; Kirk JM
Horm Res; 2006; 65(1):18-22. PubMed ID: 16357486
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
Gonc EN; Kandemir N
Clin Endocrinol (Oxf); 2007 May; 66(5):672-7. PubMed ID: 17381489
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone treatment and fat redistribution in children born small for gestational age.
De Schepper J; Thomas M; Beckers D; Craen M; Maes M; de Zegher F
J Pediatr; 2008 Mar; 152(3):327-30. PubMed ID: 18280835
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone (GH) secretion and response to GH therapy after total body irradiation and haematopoietic stem cell transplantation during childhood.
Bakker B; Oostdijk W; Geskus RB; Stokvis-Brantsma WH; Vossen JM; Wit JM
Clin Endocrinol (Oxf); 2007 Oct; 67(4):589-97. PubMed ID: 17590170
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
Craig ME; Cowell CT; Larsson P; Zipf WB; Reiter EO; Albertsson Wikland K; Ranke MB; Price DA;
Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
